A beleaguered Celgene $CELG, which was reportedly in merger talks with Bristol-Myers $BMY since September, had hatched a plan to sweeten the pot for its executive team ahead of the historic $74 billion deal announced on Thursday. In an SEC filing filing posted on Friday, Celgene said its CEO, CFO, president of research & early … Continue reading Celgene sweetened the pot for exec team ahead of Bristol-Myers merger announcement